ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically...Show More
competitor of
Metrics
marketSTOCKS
msh_idCOM:ARCABIO
localeus
websitehttps://arcabio.com/
ipo_date1997-08-08
primary_stock_msh_idNASDAQ:ABIO
source_reff7e7780b-30ae-4456-a9fe-c2c86daa7499
products_or_servicesDevelopment of monoclonal antibodies for the treatment of dermatologic and inflammatory diseases.